N PREVIOUS REPORTS we identified several risk factors that significantly affected patient and graft survival.!.:! Of these. four were major Immunologic risk factors: the number of intestinal allograft rejections. high blood FK 506 levels. high dose steroid requirements. and the need for adjunct OKT3 therapy. The remaining significant risk factors were the operative and cold ischemia times. number of previous abdominal surgeries. cytomegaloviral (CMV) and post-transplant Iymphoproliferative diseases. To decrease the immunosuppressive requirements and improve survival outcome. we declared a I year moratOrIum in 1994. pending the results of extensive clarifying investigations bv Murase et al in rats: 1 When the p~og;am reopened. ~o major changes in management strategy were instituted. One was an attempt to avoid, when possible. the transplantation of organs from CMV-positive donors to C:'1V-negative recipients. The second change was to give perioperative adjunct donor bone marrow when this was available. in order to take advantage of the more tolerogenic profile of bone marrow cells compared to that of the IIltestinal passenger leukocytes: 1 -o Other adopted strategies were careful patient selection. exclusion of the cnlon from the intestinal allograft. and monitoring of Epstein-Barr virus (EBV) infection by serial quantitative EBV polymerase chain reaction (peR) measurements.
I
N PREVIOUS REPORTS we identified several risk factors that significantly affected patient and graft survival.!.:! Of these. four were major Immunologic risk factors: the number of intestinal allograft rejections. high blood FK 506 levels. high dose steroid requirements. and the need for adjunct OKT3 therapy. The remaining significant risk factors were the operative and cold ischemia times. number of previous abdominal surgeries. cytomegaloviral (CMV) and post-transplant Iymphoproliferative diseases. To decrease the immunosuppressive requirements and improve survival outcome. we declared a I year moratOrIum in 1994. pending the results of extensive clarifying investigations bv Murase et al in rats: 1 When the p~og;am reopened. ~o major changes in management strategy were instituted. One was an attempt to avoid, when possible. the transplantation of organs from CMV-positive donors to C:'1V-negative recipients. The second change was to give perioperative adjunct donor bone marrow when this was available. in order to take advantage of the more tolerogenic profile of bone marrow cells compared to that of the IIltestinal passenger leukocytes: 1 -o Other adopted strategies were careful patient selection. exclusion of the cnlon from the intestinal allograft. and monitoring of Epstein-Barr virus (EBV) infection by serial quantitative EBV polymerase chain reaction (peR) measurements.
MATERIALS AND METHODS
We report here our overall long-term results With 115 intestmal transplantation in 109 consecutive pallents that were transplanted over S years. Of these b4 (59r~) were children and 45 (41 '.''') were adults. The causes of intestinal failure were short gut syndrome (SGS) in 119 (Sl~). dysmotility syndrome in II (10','",). intestinal neoplasm in 0 (0%). and enterocytc dvsfunction in 3 (3%). The leading causes of SGS were vascular occlUSion. Crohn's disease. and trauma in adults and volvulus, ga~troschisis. atresia and necrotizing enterocolitis in children. The intestlIlc was engrafted alone (n 43). or as part of a compOSite gratt (n = 72). before and after the moratorium. All of the is()lated intesllnal recipients were sutferin1! from frequent ccntralllIlc SCpSIS. Of the last 55 recipients. 23 were infused with bone marrow. the distinction from the other 32 being the willingness of the donor family to permit the extra procurement procedure. The surgical techniques of the donor and recipient operation and details of bone marrow augmentation are fully described elsewhere. 7 -lO The management of the intestinal allograft recipients is fully described elsewhere. 11 The immunosuppressive therapy was based on FK 506 and prednisone. Cyclophosphamide was given to 23 patients after the moratorium at a dose of 2 to 3 mg/kgld for 4 weeks and then switched to mycophenolate mofetil (15 to 30 mgJkgJd) or azathioprine. In a few cases. azathioprine was given as a third drug from the outset. The level of mamtenance immunosuppression was individualized and adjusted hased on the clinical course of each patient with the intentlon to reduce the drug dosage and levels whenever pOSSible. Episodes of rejection were treated with adjustments of FK 506 dose and/or supplemental prednisone. OKT3 was given only as a rescue therapy. Upward dose adjustments of mycophenolate mofetil. azathioprine. or steroids. were frequently needed to compensate for FK-506 dose reductions mandated hy FK 506-related adverse effects. Patient and graft survival curves were generated using the Kaplan-Meier method and group comparisons .... ere performed using the log-rank test.
RESULTS

Survival
The overall cumulative patient survival is T2q at 1 year and -+~o/c at 5 years with a graft survival rate of M% and 40%. respectively. With a mean follow-up of ~.() ::: 29 months (range. 1 to 94 months). 31 patients are alive with good nutrition heyond the third postoperative year and 18 are well he yond the 5-year mile stone. The survival benefits of intestinal transplantation has been hetter (P = .57) achieved among children compared to adults with the best outcome among patients he tween 2 and 17 years of age. in whom the 5-year cumulative survival rate was 68%. Although hoth the isolated intestinal and composite visceral grafts had similar (P = .72) survival rates. the cumulative risk of graft loss due to rejection was significantly (P = .045) higher among the isolated intestine. The Kaplan-Meier The other two (3.5%) patients are receiving partial intr,lvenous support while recovering from a recent episode of moderate to severe rejection. :--10 clinical or histopathologic evidences of disease recurrence has been documented during the 8 years of follow-up. To date. no attempts have been made to electively wean any of the intestinal recipients. including the hone marrow augmented cases. off immunosuppression.
Cost Analysis
The 
